

Parma, 6 July 2012

**MINUTES OF THE 27<sup>th</sup> PLENARY MEETING  
OF THE SCIENTIFIC PANEL ON FOOD CONTACT MATERIALS,  
ENZYMES, FLAVOURINGS AND PROCESSING AIDS (CEF)  
Held in Parma on 22 - 24 May 2012  
Adopted on 4 July 2012**

**AGENDA:**

**Table of Contents**

10	1. Welcome, apologies for absence .....	3
11	2. Adoption of the agenda.....	3
12	3. Declarations of interest.....	3
13	4. Matters arising from the 26 <sup>th</sup> Plenary Meeting (20- 22 March 2012).....	3
14	5. General information from the EFSA, the Commission and the Chair .....	3
15	6. Flavourings .....	3
16	6.1. Flavouring group evaluations .....	4
17	7. Food contact materials.....	6
18	7.1. Phenol .....	6
19	7.2. Substances for use in plastics.....	6
20	7.3. Active and intelligent substances.....	6
21	7.4. Recycling processes .....	7
22	8. AOB.....	7
23	ANNEX I: interests & actions resulting from the screening of specific declaration of interests .....	8

26  
27  
28  
29  
30

**MINUTES OF THE 27<sup>th</sup> PLENARY MEETING  
OF THE SCIENTIFIC PANEL ON FOOD CONTACT MATERIALS,  
ENZYMES, FLAVOURINGS & PROCESSING AIDS (CEF)**

---

31 **PARTICIPANTS**

32 Panel Members:

33 Ulla Beckman Sundh, Mona-Lise Binderup (2<sup>nd</sup> and 3<sup>rd</sup> days), Leon Brimer, Laurence Castle,  
34 Karl-Heinz Engel, Roland Franz, Nathalie Gontard, Rainer Gürtler (2<sup>nd</sup> and 3<sup>rd</sup> days), Trine  
35 Husøy, Klaus-Dieter Jany, Catherine Leclercq, Jean-Claude Lhuguenot, Wim C. Mennes,  
36 Maria Rosaria Milana (1<sup>st</sup> day), Maria de Fátima Poças, Iona Pratt, Kettil Svensson, Fidel  
37 Toldrá, Detlef Wölfle.

38 Invited Experts, hearing experts:

39 Vibe Beltoft (item 6)

40

41 European Commission:

42 Sirkku Heinimaa (item 6)

43 Bastiaan Schupp (item 7)

44 EFSA FIP Unit:

45 Scientific staff: Alexandre Feigenbaum, Claudia Heppner, Dimitrios Spyropoulos, Anne  
46 Theobald, Eric Barthélémy, Cristina Croera, Kim Rygaard Nielsen, Anna F. Castoldi, Alina  
47 Lupu, Andrea Terron, Maria Carfi.

48 Administrative staff: Eva Maria Ferrari, Hanne Pedersen.

49

50

51

52 **1. WELCOME, APOLOGIES FOR ABSENCE**

53 **2. ADOPTION OF THE AGENDA**

54 The agenda was adopted.

55 **3. DECLARATIONS OF INTEREST**

56 Declarations of interest were recorded and evaluated in compliance with EFSA's policy on  
57 declarations of interest:

58 <http://www.efsa.europa.eu/en/efsawho/doi.htm>

59 See Annex I

60 **4. MATTERS ARISING FROM THE 26<sup>TH</sup> PLENARY MEETING (20- 22 MARCH 2012)**

61 The minutes of the 26<sup>th</sup> Plenary meeting were adopted after editorial changes.

62 They can be seen on:

63 <http://www.efsa.europa.eu/en/events/event/120320b.htm>

64

65 **5. GENERAL INFORMATION FROM THE EFSA, THE COMMISSION AND THE CHAIR**

66 Claudia Heppner, appointed as Head of the FIP Unit from 1<sup>st</sup> June 2012, introduced herself to the  
67 Panel.

68 The programme of the EFSA Colloquium on low dose effects and non monotonic dose responses  
69 (June 14-15) was presented.

70 The Panel was informed that the Scientific Committee of EFSA has adopted on May 22<sup>nd</sup> its opinion  
71 on TTC.

72 The progress of the work of the two working groups on BPA (toxicity and exposure assessment) was  
73 presented.

74

75 **6. FLAVOURINGS**

76

77 **Smoke flavouring Primary Product SmokEz C-10**

78 *(EFSA-Q-2012-00452)*

79 The opinion on the primary product SmokEz C10 was presented and thoroughly discussed. The Panel  
80 requested further information on the representativeness of the primary product and suggested additions  
81 to the opinion.

82 The opinion will be re-discussed after appropriate changes at the July Panel meeting.

83

84 **Smoke flavouring Primary Product SmokEz Enviro C-23**

85 *(EFSA-Q-2012-00453)*

86 A similar argumentation and conclusion as for SmokEz C10 was brought forward for the smoke  
87 flavouring SmokEz enviro 23.

88 The opinion will be re-discussed after appropriate changes at the July Panel meeting.

89

## 90 **6.1. Flavouring group evaluations**

91 According to Regulation 1565/2000 of 18 July 2000 and to recent requests from Commission.

### 92 **FGE.201Rev1**

93 2-Alkylated aliphatic acyclic  $\alpha,\beta$ -unsaturated aldehydes and precursors with or without additional  
94 double-bonds from chemical subgroup 1.1.2 of FGE.19.  
95 (*EFSA-Q-2012-00243, EFSA-Q-2012-00072, EFSA-Q-2012-00071, EFSA-Q-2012-00070, EFSA-Q-*  
96 *2011-01088, EFSA-Q-2011-01087, EFSA-Q-2011-01086, EFSA-Q-2011-01085, EFSA-Q-2011-*  
97 *01084, EFSA-Q-2011-01083, EFSA-Q-2011-01082*)

98 The present FGE.201Rev1, corresponding to subgroup 1.1.2 of FGE.19, concerns eight  $\alpha,\beta$ -  
99 unsaturated aldehydes, with or without additional double bonds, [FL-no: 05.033, 05.090, 05.095,  
100 05.105, 05.107, 05.126, 05.130 and 05.178] and three precursors for such aldehydes [FL-no: 02.174,  
101 09.177 and 09.931].

102 The genotoxicity concern with respect to this group of substances due to the presence of an  $\alpha,\beta$ -  
103 unsaturated aldehyde group (or precursor for this) could not be ruled out based on the genotoxicity  
104 data and the (quantitative) structure-activity relationship (Q)SAR predictions available.

105 In response to the Panel request expressed in FGE.201, the Flavouring Industry has submitted  
106 additional genotoxicity data on two substances, 2-methylpent-2-enal [FL-no: 05.090] and 2  
107 methylcrotonaldehyde [FL-no: 05.095], from this subgroup.

108 The new data were evaluated and the draft opinion was discussed and modified.

109 Based on the submitted data, the Panel concluded that there is some evidence for [FL-no: 05.095] and  
110 an indication for [FL-no: 05.090] to show a potency for the induction of gene mutations *in vitro*.  
111 Furthermore, the Panel considered that the mutagenicity hazard could not be cleared by the endpoints  
112 evaluated in the *in vivo* micronucleus assay and that further data are required in order to clarify the  
113 genotoxic potential of this subgroup. A Comet assay performed with [FL-no: 05.095] and performed  
114 on liver, blood and first site of contact was considered as a preferred option to further investigate the  
115 genotoxicity *in vivo*.

116 In conclusion, the available data do not rule out the concern for genotoxicity.

117 The draft opinion was adopted. The full opinion is available through:

118 <http://www.efsa.europa.eu/en/efsajournal/pub/2749.htm>

119

### 120 **FGE.222**

121 Consideration of genotoxicity data on representatives for  $\alpha,\beta$ -unsaturated furyl derivatives with the  
122  $\alpha,\beta$ -unsaturation in the side chain from subgroup 4.6 of FGE.19.  
123 (*EFSA-Q-2012-00392, EFSA-Q-2012-00391, EFSA-Q-2012-00251, EFSA-Q-2012-00250, EFSA-Q-*  
124 *2012-00249, EFSA-Q-2012-00248*)

125 The present FGE.222, corresponding to subgroup 4.6 of FGE.19, concerns six furyl derivatives with a  
126  $\alpha,\beta$ -unsaturated carbonyl in the side chain, which is structural alert for genotoxicity. The data on  
127 genotoxicity previously available did not rule out the concern for genotoxicity.

128 The Industry has submitted data concerning genotoxicity studies for the two representative substances,  
129 3-(2-furyl)acrylaldehyde [FL-no: 13.034] and 4-(2-furyl)but-3-en-2-one [FL-no: 13.044], for this  
130 subgroup.

131 The new data were evaluated and the draft opinion was discussed and modified.

132 Based on the data submitted, the Panel considered that in order to clarify the clastogenic and  
133 aneugenic potential of 4-(2-furyl)but-3-en-2-one [FL-no: 13.044], an *in vivo* Comet assay should be  
134 performed and for 3-(2-furyl)acrylaldehyde [FL-no: 13.034], an *in vivo* combined Comet and  
135 micronucleus assay should be performed.

136 In conclusion, the available data do not rule out the concern for genotoxicity.

137 The draft opinion was adopted. The full opinion is available through:

138 <http://www.efsa.europa.eu/en/efsajournal/pub/2748.htm>

139

#### 140 **FGE.29Rev1**

141 Styrene

142 (*EFSA-Q-2011-01014*)

143 A note on styrene was prepared by the genotoxicity working group and discussed at the Panel meeting.  
144 The Panel supported the outcome provided by the genotoxicity working group that the available data  
145 on genotoxicity for Styrene by oral route are insufficient to clear the genotoxicity concern and bring  
146 styrene through the Procedure as a flavouring substance. The genotoxicity working group is  
147 recommending an *in vivo* Comet assay in the rat in order to clear the genotoxicity concern of styrene  
148 by oral administration.

149

#### 150 **FGE.07Rev4**

151 Saturated and unsaturated aliphatic secondary alcohols, ketones and esters of secondary alcohols and  
152 saturated linear or branched-chain carboxylic acids.  
153 (*EFSA-Q-2012-00510, EFSA-Q-2012-00509, EFSA-Q-2012-00508, EFSA-Q-2012-00507, EFSA-Q-*  
154 *2012-00506*)

155 It will be on the Agenda of the July Panel meeting.

156

#### 157 **FGE.08Rev5**

158 Aliphatic and alicyclic mono-, di-, tri-, and polysulphides with or without additional oxygenated  
159 functional groups.  
160 (*EFSA-Q-2012-00511*)

161 Due to lack of time, the discussion was deferred to the next Panel meeting.

162

#### 163 **FGE.09Rev4**

164 Secondary alicyclic saturated and unsaturated alcohols, ketones and esters containing secondary  
165 alicyclic alcohols.  
166 (*EFSA-Q-2011-01246, EFSA-Q-2011-01245, EFSA-Q-2011-01244, EFSA-Q-2011-01243, EFSA-Q-*  
167 *2011-01242*)

168 Due to lack of time, the discussion was deferred to the next Panel meeting.

169

#### 170 **FGE.94Rev1**

171 Consideration of aliphatic amines and amides evaluated in addendum to the JECFA group aliphatic  
172 and aromatic amines and amides by JECFA (68<sup>th</sup> meeting).  
173 (*EFSA-Q-2012-00079, EFSA-Q-2011-01120*)

174 The draft opinion was adopted. The full opinion is available through:  
175 <http://www.efsa.europa.eu/en/efsajournal/pub/2747.htm>

176

## 177 **FGE.99**

178 Consideration of Furanone derivatives evaluated by the JECFA (63<sup>th</sup> and 65<sup>th</sup> meeting).  
179 (*EFSA-Q-2007-00608, EFSA-Q-2007-00597, EFSA-Q-2007-00595, EFSA-Q-2007-00594, EFSA-Q-*  
180 *2007-00577*)

181 Due to lack of time, the discussion was deferred to the next Panel meeting.

182

## 183 **FGE.312**

184 3-[(4-Amino-2,2-dioxido-1H-2,1,3-benzothiadiazin-5-yl)oxy]-2,2-dimethyl-N-propylpropanamide.  
185 (*EFSA-Q-2012-00078*)

186 Due to lack of time, the discussion was deferred to the next Panel meeting.

187

## 188 **7. FOOD CONTACT MATERIALS**

### 189 **7.1. Phenol**

190 The Panel discussed the re-assessment of the TDI for phenol and examined the draft report on phenol  
191 immunotoxicity in mice recently received from the US NTP/NIEHS. The Panel could not conclude on  
192 the TDI for phenol based on this draft report.

193 Both the Beyrouty and IITRI study reports (which the Panel wished to review in depth in order to  
194 conclude on a TDI) are only available at BfR. The scientific secretariat will ask BfR for a copy of  
195 these studies and will request an extension of the deadline.

196

### 197 **7.2. Substances for use in plastics**

#### 198 **FCM substance No 958**

199 Methacrylic acid, 2,3-epoxypropyl ester, copolymer with acrylic and/ or methacrylic acid, alkyl (C1-  
200 C4) esters  
201 (*EFSA-Q-2006-00203*)

202 The draft opinion was discussed, modified and adopted. The full opinion is available through:  
203 <http://www.efsa.europa.eu/en/efsajournal/pub/2744.htm>

204

#### 205 **FCM substance No 995**

206 2-Hydroxypropyl methacrylate  
207 (*EFSA-Q-2011-01239*)

208 The draft opinion was discussed, modified and adopted. The full opinion is available through:  
209 <http://www.efsa.europa.eu/en/efsajournal/pub/2745.htm>

210

### 211 **7.3. Active and intelligent substances**

212 **Liquid absorber based on:** open-cell expanded polystyrene, manufactured with talc and alkyl(C8-  
213 C22) sulphonic acid (salts)  
214 (*EFSA-Q-2011-00762*)

215 The draft opinion was discussed, modified and adopted. The full opinion is available through:  
216 <http://www.efsa.europa.eu/en/efsajournal/pub/2746.htm>

217

#### 218 **7.4. Recycling processes**

##### 219 **Reg. No RECYC008, RECYC025, RECYC024 and RECYC027**

220 Draft grouped opinion on LuxPET, PolyQuest, Jayplas and CIER recycling processes based on  
221 Vacurema Prime technology  
222 (*EFSA-Q-2009-00773; EFSA-Q-2010-00022; EFSA-Q-2010-00003; EFSA-Q-2010-00048*)

223 The draft opinion was discussed and changes were noted. A revised version will be scheduled for the  
224 next Panel meeting.

225

##### 226 **Reg. No RECYC004**

227 PETUK SSP

228 (*EFSA-Q-2009-00706*)

229 The discussion was deferred to the next Panel meeting.

230

##### 231 **Reg. No RECYC012, RECYC042, RECYC054, RECYC068 and RECYC080**

232 Draft grouped opinion on recycling processes Preformia, STF, MPTS, PET to PET and Eco Plastic  
233 based on Starlinger IV+ ® technology  
234 (*EFSA-Q-2010-00868, EFSA-Q-2009-00899, EFSA-Q-2009-00960, EFSA-Q-2011-01238, EFSA-Q-*  
235 *2010-01173*)

236 The discussion was deferred to the next Panel meeting.

237

#### 238 **8. AOB**

239 None.

240

241 **ANNEX I: interests & actions resulting from the screening of specific declaration of interests**

242 Dr. Franz declared interest for the draft group opinion on “recycling processes based on Vacurema  
243 Prime technology (LuxPET, PolyQuest, Jayplas and CIER)” as his organisation has prepared the  
244 dossiers for these applications. He declared the same interest for the draft group opinion on “recycling  
245 processes based on Starlinger IV+ ® technology (on Preformia, STF, MPTS, PET to PET and Eco  
246 Plastic)”. This was considered a conflict of interest and the expert left the room when the opinion was  
247 discussed.

248  
249 Dr. Franz also declared interest for the recycling process PETUK. Although he has not carried out any  
250 experimental contract work for the applicant, this interest presents a conflict since his laboratory has  
251 prepared many dossiers on PET recycling for other applicants. The expert left the room during the  
252 discussion.

253  
254 Dr. Wölfle provided preparatory work documents in the field of food contact materials for the  
255 substances “methacrylic acid, 2,3-epoxypropyl ester, copolymer with acrylic and/ or methacrylic acid,  
256 alkyl (C1-C4) esters” and “2-hydroxypropyl methacrylate”, in the context of the contract between  
257 EFSA and BfR. This was considered as a conflict of interest because he could not act at the same time  
258 as a representative of the contractor and as a member of the Panel with voting rights. He was allowed  
259 to stay in the room to answer to specific technical questions but he did not participate in the discussion  
260 of the opinions. Another Panel member presented the draft opinion.

261  
262 Dr. Castle declared interest for the substance “methacrylic acid, 2,3-epoxypropyl ester, copolymer  
263 with acrylic and/ or methacrylic acid, alkyl (C1-C4) esters” as his Institute received fees for work done  
264 under contract with the applicant for the substance under evaluation and these data have been included  
265 in the application. This was considered as a conflict and the expert left the room during the discussion.  
266

267 Dr. Milana declared that she had been involved in a project funded by Istituto Superiore della Sanità  
268 (public organisation) and by a federation of food industries (mineral water) to assess the scope of  
269 recycled PET. Since this was a pre-normative research and as it was not run for the benefit of a single  
270 company but for the entire sector, this is not a conflict.